Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales mile...
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...
The oversubscribed capital raise was led by existing venture capital investors: U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and...
Seven major research projects to receive more than £14 million to develop new tests, treatments and devices for neurodegenerative diseases includin...
Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial gen...
Under the planned partnership, Ginkgo and the Serbian Ministry of Science, Technological Development and Innovation will work to establish a Startup Accele...
Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round. This funding round positions Gero to con...
“Our ongoing partnership with Bayer leverages the full suite of our Twist Biopharma Solutions offering of antibody discovery services to identify the...
--Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, announc...
Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform ...
Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of c...
-Brain diagnostics innovator BrainScope announced a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s ...
"We are thrilled to receive this investment from KITVEN and Conscience Multi Family Office," said Dr. Chandrashekaran. "This funding will empower us to f...
Series C is led by Koch Disruptive Technologies and includes Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Dech...
© 2024 Biopharma Boardroom. All Rights Reserved.
